OncLive TV

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL

August 3rd 2021

Christopher Flowers, MD, discusses efforts to improve the frontline standard of care in diffuse large B-cell lymphoma.

Dr. Ozguroglu on the Individualization of Treatment in NSCLC

August 3rd 2021

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Dr. Puri on Clinically Relevant Biomarkers in SCLC

August 3rd 2021

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer. 

Dr. Manasanch on Key Takeaways From CASSIOPEIA in Multiple Myeloma

August 3rd 2021

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

August 3rd 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Dr. Kumar on Patient Considerations for Treatment in Relapsed/Refractory MCL

August 3rd 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Dr. Landgren on Novel Approaches Generating Excitement in Myeloma

August 3rd 2021

C. Ola Landgren, MD, PhD, discusses novel therapeutic approaches that are generating excitement in multiple myeloma.

Dr. Sam on Managing ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 3rd 2021

Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Morgan on the Differences in Low- and High-Risk Multiple Myeloma

August 2nd 2021

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Dr. Puri on the Rationale to Evaluate Real-World Multiomic Characterization of SCLC Subtypes

August 2nd 2021

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC

August 2nd 2021

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLC

August 2nd 2021

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.

Dr. Cohen on the Clinical Implications of the GALAXY Trial in CRC

August 2nd 2021

Stacey A. Cohen, MD, discusses the clinical implications of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Dr. Roboz on the Importance of Genomic Analysis in AML

August 2nd 2021

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

Dr. Manasanch on Outcomes With Elranatamab in Multiple Myeloma

August 2nd 2021

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 1st 2021

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Dr. Willmott on Using Genetic Testing to Inform PARP Inhibitor Selection in Ovarian Cancer

July 29th 2021

Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results.